Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Analysts predict that GLP-1 drugs like Zepbound and Ozempic will be highly profitable, reshaping the pharmaceutical industry by treating obesity. Lilly's sales have soared due to demand for their obesity and diabetes drugs, while Amgen is also finding success in the obesity drug market. The FDA has approved a rival to Lilly's weight loss drug Wegovy, providing insights into the impact of these developments on the industry.AbbVie's CEO is stepping down, with COO Robert Michael set to succeed him. Iovance is gearing up for the launch of its 'til' cell therapy at $515,000 per patient. AstraZeneca has received FDA approval for Tagrisso in combination with chemotherapy for metastatic lung cancer. The biosimilars market in the US is growing after a slow start. Other news includes Bayer cutting its dividend, interest in Sanofi's consumer arm, Teva Pharm focusing on its unified drug business, and more than half of US newborns receiving RSV protection.The FDA has placed a hold on Rapt Therapeutics' Zelnecirnon after a patient experienced liver failure during trials for atopic dermatitis and asthma. Meanwhile, Astrazeneca's Tagrisso continues to succeed in treating non-small cell lung cancer. Other top stories include Lilly surpassing J&J in market cap, Daiichi Sankyo investing in ADC manufacturing capacity, and Bristol Myers Squibb developing advanced cancer therapies. Pfizer's ulcerative colitis drug has been approved in Europe, while AstraZeneca aims to excel in the kidney disease space despite setbacks.The importance of improving outpatient care and identifying insights to support maternal morbidity action plans is discussed. Healthcare professionals are encouraged to view online data to trend risk-adjusted maternal outcomes throughout pregnancy and the postpartum period to enhance maternal health. Healthcare Dive offers the opportunity to reach a large audience of healthcare and health IT executives through advertising. Subscribers can opt for a weekly newsletter or unsubscribe from daily updates.

Support the Show.